Trial Profile
Intratumoral Injection of SD-101, an Immunostimulatory CpG, in Combination With BMS-986178 and Local Radiation in Low-Grade B-Cell Lymphomas
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs BMS 986178 (Primary) ; BMS 986178 (Primary) ; Nelitolimod (Primary)
- Indications B-cell lymphoma
- Focus Adverse reactions
- 12 Dec 2023 Results assessing Loss of the OX40 Target in Lymphoma Patients after Combining an Anti-OX40 Agonist Antibody with in Situ Vaccination presented at the 65th American Society of Hematology Annual Meeting and Exposition
- 20 Nov 2023 Planned End Date changed from 10 Oct 2023 to 10 Oct 2024.
- 09 Nov 2023 Planned primary completion date changed from 9 Oct 2023 to 9 Oct 2024.